U.S. Minimally Invasive Urinary Incontinence Therapy Systems Market

Introduction

Abstract

Incontinence may be defined as the involuntary loss of bladder or bowel control. In the United States (U.S.), urinary incontinence (UI) afflicts an estimated 50 million people. According to the National Association for Continence (NAFC), approximately 75% to 80% of the UI populations are women, with 9 million to 13 million suffering severe symptoms.

Although UI is an extremely common problem, and has a significant impact on quality of life, the vast majority of those who experience the condition do not undergo treatment, in part due to cost, embarrassment, or fear of risky surgical procedures. There is therefore a very strong demand for less costly, less invasive and more tolerable, discreet, nonsurgical UI therapies.

While current economic conditions and other factors continue to restrain market growth, the market for minimally invasive UI therapy systems is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $190 million in 2010, the U.S. Minimally Invasive Urinary Incontinence Therapy Systems market is expected to increase at a healthy compound annual rate of 2.7%, with sales reaching more than $220 million in 2015. The market is expected to benefit not only from strong demand but from highly positive demographic trends, including a large, growing UI population and limited options for truly effective therapeutic alternatives.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include injectable urethral bulking agents; urethral sling systems; implantable sacral nerve neurostimulators; nonsurgical office-based neuromodulation/percutaneous tibial nerve stimulation; and other nonsurgical treatments.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

Report Statistics

• Publication Date: July 2011
• Total Number of Pages: 156
• Total Number of Exhibits: 49
• Total Number of Company Profiles: 10

Table of Contents

Table of Contents

EXECUTIVE SUMMARY

• i. Types of Urinary Incontinence
• ii. Stress Urinary Incontinence
• iii. Overactive Bladder and Urge Incontinence
• iv. Treatment
  • a. Prescription Drug Therapy
  • b. Botulinum Toxin
  • c. Bulking Agents
  • d. Implantable Neurostimulation
  • e. Percutaneous Tibial Nerve Stimulation
  • f. Urethral Slings
  • g. Surgical Options
  • v. Minimally Invasive Urinary Incontinence Therapy Systems Market
  • a. Procedure Volumes
  • b. Market Forecast
• vi. Methodology

• Exhibit ES-1: Minimally Invasive Urinary Incontinence Therapy, Procedure Volumes Forecast, 2010-2015
• Exhibit ES-2: Minimally Invasive Urinary Incontinence Therapy Systems, Market Forecast, 2010-2015

1. CLINICAL OVERVIEW OF URINARY INCONTINENCE

• 1.1. Anatomy of the Urinary System
• 1.2. Types of Urinary Incontinence
  • 1.2.1. Stress Urinary Incontinence
    • 1.2.1.1. Causes
  • 1.2.2. Overactive Bladder and Urge Incontinence
    • 1.2.2.1. Causes
• 1.3. Treatment
  • 1.3.1. Prescription Drug Therapy
  • 1.3.2. Botulinum Toxin
  • 1.3.3. Bulking Agents
  • 1.3.4. Sacral Nerve Stimulation
    • 1.3.4.1. Implantable Neurostimulation
    • 1.3.4.2. Percutaneous Tibial Nerve Stimulation
• 1.3.5. Urethral Slings
• 1.3.6. Surgical Options

• Exhibit 1-1: Urinary Voiding and Afferent Signaling
• Exhibit 1-2: Sacral Neuromodulation with an Implanted Electrical Stimulator

2. MINIMALLY INVASIVE URETHRAL BULKING AGENTS

• 2.1. Selected Products
  • 2.1.1. Contigen
  • 2.1.2. Coaptite
  • 2.1.3. Durasphere EXP
  • 2.1.4. Macroplastique
  • 2.1.5. Bulkamid
• 2.2. Market Analysis
  • 2.2.1. Procedure Volumes
  • 2.2.2. Market Forecast
  • 2.2.3. Competitive Analysis

• Exhibit 2-1: The Coaptite Injectable Implant Procedure
• Exhibit 2-2: The Macroplastique Urethral Bulking Agent
• Exhibit 2-3: Macroplastique Treatment, Key Efficacy Results at 12 Months
• Exhibit 2-4: Macroplastique Treatment, Key Adverse Events
• Exhibit 2-5: Minimally Invasive Urethral Bulking Agent Therapy, Procedure Volumes Forecast, 2010-2015
• Exhibit 2-6: Minimally Invasive Urethral Bulking Agents, Market Forecast, 2010-2015
• Exhibit 2-7: 2010, Minimally Invasive Urethral Bulking Agents Market, Share by Supplier

3. MINIMALLY INVASIVE URETHRAL SLING SYSTEMS

• 3.1. Selected Products
  • 3.1.1. American Medical Systems/Endo Pharmaceuticals
    • 3.1.1.1. Urethral Slings for Women
    • 3.1.1.2. Urethral Slings for Men
  • 3.1.2. Bard Medical/C.R. Bard
  • 3.1.3. Boston Scientific
  • 3.1.4. Caldera Medical
  • 3.1.5. Coloplast
  • 3.1.6. Cook Medical/Cook Group
  • 3.1.7. Ethicon/Johnson & Johnson
  • 3.1.8. Promedon
• 3.2. Market Analysis
  • 3.2.1. Procedure Volumes
  • 3.2.2. Market Forecast
  • 3.2.3. Competitive Analysis

• Exhibit 3-1: 2011, Selected Urethral Sling Systems
• Exhibit 3-2: The MiniArc Precise Single-Incision Sling System
• Exhibit 3-3: The MiniArc Single-Incision Sling
• Exhibit 3-4: The Monarc Subfascial Hammock
• Exhibit 3-5: Suprapubic and Transobturator Approaches to Mid-Urethral SlingPlacement Using the BioArc SP and BioArc TO Sling Systems
• Exhibit 3-6: 12-Step Mid-Urethral Sling Implant Procedure Using theBioArc SP Sling System
• Exhibit 3-7: The In-Fast Ultra Transvaginal Sling
• Exhibit 3-8: The Ajust Adjustable Single-Incision Sling
• Exhibit 3-9: The Align Urethral Support System
• Exhibit 3-10: The PelviLace Biourethral Support System
• Exhibit 3-11: The Advantage Fit System
• Exhibit 3-12: Components of the Advantage Transvaginal Mid-Urethral Sling System
• Exhibit 3-13: Steps in a Mid-Urethral Sling Implant Procedure Using the Advantage Sling System
• Exhibit 3-14: The Desara Sling System
• Exhibit 3-15: Mesh Integrity, Comparison of the Desara Mesh with Other Slings
• Exhibit 3-16: The Aris Transobturator Sling System
• Exhibit 3-17: The Biodesign Tension-Free Urethral Sling
• Exhibit 3-18: The TVT ABBREVO Continence System
• Exhibit 3-19: Safety Advantages of the TVT ABBREVO Procedure
• Exhibit 3-20: Comparable Clinical Improvement at 12 months, Modified TVTObturator System versus the Unaltered TVT Obturator System
• Exhibit 3-21: TVT Tension-Free Support for Incontinence and TVT EXACT Continence Systems, Comparative Perforation and Voiding Dysfunction Rates
• Exhibit 3-22: Comparative Benefits of the TVT SECUR Mini Single-Incision Sling as Compared with the MiniArc Sling System
• Exhibit 3-23: The Ophira Mini Sling System
• Exhibit 3-24: The Argus Adjustable Male Sling System
• Exhibit 3-25: Minimally Invasive Urethral Sling Implantation, Procedure Volumes Forecast, 2010-2015
• Exhibit 3-26: Minimally Invasive Urethral Sling Systems, Market Forecast, 2010-2015
• Exhibit 3-27: 2010, Minimally Invasive Urethral Sling Systems Market, Share by Supplier

4. SACRAL NERVE STIMULATION

• 4.1. Selected Products
  • 4.1.1. InterStim Therapy System
  • 4.1.2. Urgent PC Neuromodulation System
• 4.2. Market Analysis

• Exhibit 4-1: The InterStim Therapy System
• Exhibit 4-2: InterStim Therapy, 12-Month and 5-Year Sustained Clinical Efficacy
• Exhibit 4-3: The Sacral Plexus
• Exhibit 4-4: The Urgent PC Neuromodulation System
• Exhibit 4-5: Summary of a Meta-Analysis of Percutaneous Tibial Nerve Stimulation Using the Urgent PC Neuromodulation System

5. NON SURGICAL INCONTINENCE THERAPIES

• 5.1. Selected Products
  • 5.1.1. Renessa System
  • 5.1.2. NeoControl Pelvic Floor Therapy System
  • 5.1.3. MS-106 Twin and MS-310 Pelvic Floor Stimulators
  • 5.1.4. Liberty System

• Exhibit 5-1: The Renessa System and Benefits of Treatment
• Exhibit 5-2: Renessa Therapy' s Place in the Spectrum of Treatment Options
• Exhibit 5-3: The Renessa Procedure and Mechanism of Action
• Exhibit 5-4: NeoControl Pelvic Floor Therapy and Mechanism of Action
• Exhibit 5-5: The MS-106 Twin and MS-310 Pelvic Floor Stimulators
• Exhibit 5-6: Liberty System Pelvic Floor Stimulator

6. COMPANY PROFILES

• 6.1. American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc.
• 6.2. C.R. Bard, Inc.
• 6.3. Boston Scientific Corporation
• 6.4. Caldera Medical, Inc.
• 6.5. Coloplast AS
• 6.6. Contura International AS/Idosan AS
• 6.7. Cook Group, Inc.
• 6.8. Johnson & Johnson
• 6.9. Medtronic, Inc.
• 6.10. Uroplasty, Inc.

U.S. Minimally Invasive Urinary Incontinence Therapy Systems Market published by Medtech Insight in August 17, 2011. This report consists of 156 Pages and the price starts from US $ 3750.